{"id":1206,"company":{"country":"GB","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2018-06-22","marketCap":489.78,"name":"Autolus Therapeutics PLC","phone":"442038296230.0","outstanding":173.68,"symbol":"AUTL","website":"https://www.autolus.com/","industry":"Biotechnology"},"price":4.29125,"year":2023,"month":11,"day":23,"weekday":"Thursday","title":"Historical Performance of Autolus Therapeutics PLC Stock Compared to Industry Benchmarks","date":"2023-11-23","url":"/posts/2023/11/23/AUTL","content":[{"section":"Introduction","text":"Autolus Therapeutics PLC is a biopharmaceutical company focused on developing and commercializing next-generation programmed T cell therapies. To assess the historical performance of Autolus Therapeutics PLC stock, we will compare it to industry benchmarks and analyze its price movements over time."},{"section":"Methodology","text":"To compare the performance of Autolus Therapeutics PLC stock against industry benchmarks, we will use a variety of metrics including price returns, total returns, and volatility. These metrics will provide a comprehensive picture of the stock's performance relative to the broader industry."},{"section":"Analysis","text":"Over the past five years, Autolus Therapeutics PLC stock has shown significant volatility. The stock price has experienced both rapid climbs and steep declines. This volatility can be attributed to various factors, including clinical trial results, regulatory news, and market sentiment towards the biopharmaceutical sector."},{"section":"Comparison to Industry Benchmarks","text":"When comparing Autolus Therapeutics PLC stock to industry benchmarks, we observe that its performance has generally followed the trend of the broader biopharmaceutical industry. However, there have been periods where Autolus Therapeutics PLC stock has outperformed or underperformed the benchmarks, indicating the stock's sensitivity to company-specific news and developments."},{"section":"Long-Term Trend","text":"In the long-term, Autolus Therapeutics PLC stock has shown an upward trend, aligning with the growth potential of the biopharmaceutical sector as a whole. Investors who have held the stock for an extended period have seen positive returns, despite short-term market fluctuations."},{"section":"Conclusion","text":"In conclusion, Autolus Therapeutics PLC stock has exhibited volatility in its historical performance, reflecting the inherent risks associated with the biopharmaceutical industry. While the stock generally moves in line with industry benchmarks, it has also demonstrated the potential for both outperformance and underperformance. Investors should carefully consider these factors and conduct further analysis before making investment decisions."}],"tags":["CrossOver100","Long","Biotechnology"],"news":[{"category":"company","date":1700112840,"headline":"Syncona reports declining asset value as investment head steps down","id":123933783,"image":"","symbol":"AUTL","publisher":"Alliance News","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=iso5ls6f7e"},{"category":"company","date":1700049600,"headline":"Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023","id":123892501,"image":"https://media.zenfs.com/en/globenewswire.com/49d8c6397e759338078474305555c4a1","symbol":"AUTL","publisher":"Yahoo","summary":"In-person and webcast event on Sunday, 10 December, 2023 at 8:00 AM PT / 4:00 PM GMTReview of pooled analysis of the ongoing FELIX Phase Ib/II study, pooled analysis from ALLCAR19 and FELIX Phase Ib studies and ALLCAR19 extension with obe-cel, as well as initial data from the AUTO8 MCARTY Phase I Study LONDON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, will host an i","url":"https://finance.yahoo.com/news/autolus-therapeutics-host-analyst-investor-120000268.html"},{"category":"company","date":1700022780,"headline":"WISH , ZION and VECO are among after hour movers","id":123907715,"image":"","symbol":"AUTL","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3214547082"},{"category":"company","date":1700019180,"headline":"12 Health Care Stocks Moving In Wednesday's After-Market Session","id":123899835,"image":"","symbol":"AUTL","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3214446360"},{"category":"company","date":1699924800,"headline":"Promising Outlook for Autolus Therapeutics: Buy Rating Based on Commercial Progress and Market Expansion Opportunities","id":123875235,"image":"","symbol":"AUTL","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3211531952"},{"category":"company","date":1699604362,"headline":"Deutsche Bank Initiates Coverage of Autolus Therapeutics plc - ADR (AUTL) with Buy Recommendation","id":123780033,"image":"","symbol":"AUTL","publisher":"Fintel","summary":"","url":"https://fintel.io/news/deutsche-bank-initiates-coverage-of-autolus-therapeutics-plc-adr-autl-with-buy-recommendation-507"}]}